REVVITY, INC. — Lobbying Disclosure | Poliscope

REVVITY, INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$1.5M

Filings

Firms Hired

Active Period

2021–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$115,000	3	1
2025	$160,000	4	1
2024	$280,000	4	1
2023	$280,000	4	1
2022	$350,000	5	1
2021	$280,000	7	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
REVVITY, INC.	$1,465,000	27

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	24
SENATE	24
Health & Human Services, Dept of (HHS)	23
Bureau of Industry and Security (BIS)	2
White House Office	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	27
Science/Technology	Science/Technology	10
Environment/Superfund	Environment/Superfund	5
Trade (domestic/foreign)	Trade (domestic/foreign)	5
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	4
Budget/Appropriations	Budget/Appropriations	3
Defense	Defense	3
Disaster Planning/Emergencies	Disaster Planning/Emergencies	3
Manufacturing	Manufacturing	3
Homeland Security	Homeland Security	3
Pharmacy	Pharmacy	3
Insurance	Insurance	3
Medicare/Medicaid	Medicare/Medicaid	3
Veterans	Veterans	3
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	1
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	1
Food Industry (safety, labeling, etc.)	Food Industry (safety, labeling, etc.)	1
Agriculture	Agriculture	1
Clean Air and Water (quality)	Clean Air and Water (quality)	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2810119th Congress

Family Cord Blood Banking Act

2026 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810 - Family Cord Blood Banking Act

Client expense: $40,000 · Firm income: —

Matched citations: H.R. 2810

H.R. 4709119th Congress

Newborn Screening Saves Lives Reauthorization Act of 2025

2026 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810 - Family Cord Blood Banking Act

Client expense: $40,000 · Firm income: —

Matched citations: HR 4709

H.R. 2810119th Congress

Family Cord Blood Banking Act

2026 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act S. 4612 SCREEN for Type 1 Diabetes Act Newborn Screening Amendment to NDAA

Client expense: $40,000 · Firm income: —

Matched citations: H.R. 2810

H.R. 4709119th Congress

Newborn Screening Saves Lives Reauthorization Act of 2025

2026 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act S. 4612 SCREEN for Type 1 Diabetes Act Newborn Screening Amendment to NDAA

Client expense: $40,000 · Firm income: —

Matched citations: HR 4709

Show 21 more cited filings

S. 4612119th Congress

SCREEN for Type 1 Diabetes Act of 2026

2026 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act S. 4612 SCREEN for Type 1 Diabetes Act Newborn Screening Amendment to NDAA

Client expense: $40,000 · Firm income: —

Matched citations: S. 4612

H.R. 2810119th Congress

Family Cord Blood Banking Act

2026 · first_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act

Client expense: $35,000 · Firm income: —

Matched citations: H.R. 2810

H.R. 4709119th Congress

Newborn Screening Saves Lives Reauthorization Act of 2025

2026 · first_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act

Client expense: $35,000 · Firm income: —

Matched citations: HR 4709

H.R. 2810119th Congress

Family Cord Blood Banking Act

2025 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Genomic sequencing Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariffs

Client expense: $30,000 · Firm income: —

Matched citations: H.R. 2810

H.R. 4709119th Congress

Newborn Screening Saves Lives Reauthorization Act of 2025

2025 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Genomic sequencing Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariffs

Client expense: $30,000 · Firm income: —

Matched citations: HR 4709

H.R. 2810119th Congress

Family Cord Blood Banking Act

2025 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Newborn Screening Saves Lives Act Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariffs

Client expense: $30,000 · Firm income: —

Matched citations: H.R. 2810

H.R. 2810119th Congress

Family Cord Blood Banking Act

2025 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act

Client expense: $30,000 · Firm income: —

Matched citations: H.R. 2810

H.R. 8882119th Congress

Main Street Competes Act

2025 · first_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Diagnostic test reimbursement and policies; Proposals related to newborn screening; Proposals related to pandemic preparedness; H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 8882

H.R. 6102116th Congress

VALID Act of 2020

2024 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

H.R. 8882116th Congress

FLOODS Act

2024 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 8882

H.R. 6102116th Congress

VALID Act of 2020

2024 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

H.R. 8882116th Congress

FLOODS Act

2024 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 8882

H.R. 6102116th Congress

VALID Act of 2020

2024 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

H.R. 8882116th Congress

FLOODS Act

2024 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 8882

H.R. 1170116th Congress

Social Security Expansion Act

2023 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 1170 Access to Future Cures Act, proposals related to expenses for storage of blood or biomaterial derived from blood

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 1170

H.R. 6102116th Congress

VALID Act of 2020

2023 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 1170 Access to Future Cures Act, proposals related to expenses for storage of blood or biomaterial derived from blood

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

H.R. 1170116th Congress

Social Security Expansion Act

2023 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 1170 Access to Future Cures Act, proposals related to expenses for storage of blood or biomaterial derived from blood

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 1170

H.R. 6102116th Congress

VALID Act of 2020

2023 · third_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 1170 Access to Future Cures Act, proposals related to expenses for storage of blood or biomaterial derived from blood

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

H.R. 1170116th Congress

Social Security Expansion Act

2023 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 1170 Access to Future Cures Act, proposals related to expenses for storage of blood or biomaterial derived from blood

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 1170

H.R. 6102116th Congress

VALID Act of 2020

2023 · second_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain H.R. 1170 Access to Future Cures Act, proposals related to expenses for storage of blood or biomaterial derived from blood

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

H.R. 6102116th Congress

VALID Act of 2020

2022 · fourth_quarter · Firm: REVVITY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

American Rescue Plan implementation COVID-19 preparedness products and services Diagnostic test reimbursement and policies H.R. 6102 VALID (Verifying Accurate Leading‐edge IVCT Development) Act of 2020 Proposals related to COVID-19 medical device regulation Proposals related to newborn screening Proposals related to preserving medical supply chain COVID-19 preparedness products and services Diagnostic test reimbursement and policies

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 6102

Source: Senate LDA